<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01538940</url>
  </required_header>
  <id_info>
    <org_study_id>CDC-NCIRD-6181</org_study_id>
    <secondary_id>1U01GH000152</secondary_id>
    <nct_id>NCT01538940</nct_id>
  </id_info>
  <brief_title>Immunogenicity of Influenza Vaccines in HIV-infected Persons in Thailand</brief_title>
  <official_title>Randomized Controlled Trial to Compare the Immunogenicity of Intramuscular Versus Intradermal Trivalent Inactivated Split Virion Influenza Vaccine in HIV-infected Men Who Have Sex With Men in Bangkok, Thailand</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centers for Disease Control and Prevention</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the efficacy of a new intradermal formulation of the trivalent
      inactivated influenza vaccine compared to the standard intramuscular vaccine in HIV-infected
      men who have sex with men in Bangkok, Thailand. Relative efficacy of the two different
      formulations of influenza vaccine will be assessed by comparing immunologic responses to
      vaccine between the two study arms.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody titers</measure>
    <time_frame>30 days</time_frame>
    <description>Frequency of 4-fold or greater increase in serum hemagglutination inhibition antibody titers against each viral strain in the vaccine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody titers</measure>
    <time_frame>6 months</time_frame>
    <description>Frequency of 4-fold or greater increase in serum hemagglutination inhibition antibody titers against each viral strain in the vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody titers</measure>
    <time_frame>12 months</time_frame>
    <description>Frequency of 4-fold or greater increase in serum hemagglutination inhibition antibody titers against each viral strain in the vaccine</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>HIV+, CD4&lt;200, ID vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV+, CD4&lt;200, IM vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV+, CD4&gt;=200, ID vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV+, CD4 &gt;=200, IM vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-, ID vaccine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-, IM vaccine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intradermal vaccine</intervention_name>
    <description>15ug</description>
    <arm_group_label>HIV+, CD4&lt;200, ID vaccine</arm_group_label>
    <arm_group_label>HIV+, CD4&gt;=200, ID vaccine</arm_group_label>
    <arm_group_label>HIV-, ID vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intramuscular vaccine</intervention_name>
    <description>15ug</description>
    <arm_group_label>HIV+, CD4&lt;200, IM vaccine</arm_group_label>
    <arm_group_label>HIV+, CD4 &gt;=200, IM vaccine</arm_group_label>
    <arm_group_label>HIV-, IM vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Thai men by nationality who have sex with men

          -  HIV-infected or HIV-uninfected men

          -  At least 18 years of age

          -  Willing and able to provide written informed consent

          -  Availability and commitment for 12 months of study follow-up (3 study visits)

        Exclusion Criteria:

          -  Men with severe allergies to chicken eggs (they will specifically be asked about
             severe egg allergies during the screening visit; appendix C1)

          -  Men &gt; 60 years of age

          -  Men who have had a severe reaction to influenza vaccine in the past

          -  Men with a history of Guillain-Barr√© Syndrome

          -  Men who received influenza vaccine within 12 months prior to enrollment

          -  Men who are on steroid therapy or other immunosuppressant medications

          -  Men who received any vaccine in the 4 weeks prior to the first study visit or who plan
             to receive a vaccine (other than influenza vaccine provided through the study
             protocol) in the 4 weeks following the first study visit

          -  Men who received an experimental agent (vaccine, drug, biologic, device, blood
             product, medication) within 1 month prior to enrollment in this study, or expect to
             receive an experimental agent during the 12 month study period

          -  Men who have any condition, in the opinion of the investigator, that would place them
             at an unacceptable risk of injury or render them unable to meet requirements of the
             protocol. (e.g., severe reaction to another vaccine, blood clotting disorder,
             inflammatory skin condition).

          -  Foreign (non-Thai) nationality
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charung Muangchana, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ministry of Health, Thailand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prasert Thongcharoen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Influenza Foundation of Thailand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Silom Community Clinic</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pornchai Sornsathapornkul, RN</last_name>
      <phone>+66-2-634-2917</phone>
      <email>fnpst@diamond.mahidol.ac.th</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.silomclinic.in.th/</url>
    <description>Website for clinic where the study is being conducted.</description>
  </link>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2012</study_first_submitted>
  <study_first_submitted_qc>February 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2012</study_first_posted>
  <last_update_submitted>September 10, 2012</last_update_submitted>
  <last_update_submitted_qc>September 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Thailand</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

